Praxis Precision Medicines (NASDAQ:PRAX) announced Friday that the company will advance its Essential3 program for its lead asset ulixacaltamide against the neurological disorder essential tremor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback